Back to News
Market Impact: 0.35
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Neurocrine Biosciences beat Q3 earnings and revenue estimates, with strong Ingrezza demand and Crenessity growth supporting momentum. The company also raised its 2026 sales guidance; the article provides no figures for the beats or guidance increase.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
NBIX0.75
More News
- Why is Neurocrine Biosciences stock surging today?
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history